Endo, Vernalis Seek First Triptan Menstrual Migraine Indication With Frova sNDA

Frovatriptan sNDA is supported by data from four studies, including two Phase III trials evaluating efficacy in short-term prevention of MM.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet